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1. Introduction
Vessels and the vascular endothelium are involved in the pathogenesis of inflammatory
rheumatic diseases a family of related disorders that include rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). In these conditions vascular
involvement is very important. This chapter aims to give an overview of the prevalence of the
different forms of vasculopathy/vasculitis that can be encountered in the RA, SLE and SSc
patients, describe their pathogenesis, and address their impact on disease severity and
outcome. All of these rheumatic diseases involve some level of underlying vasculitis.
SSc is a connective tissue disease characterized by fibrosis and vasculopathy involving
multiple organ systems. Many clinical complications of SSc are due to dysfunction of vascular
beds throughout the body. Involvement of the microvasculature leads to cutaneous and
mucosal telangiectasias, digital ulcers, and tissue ischemia. If medium-sized blood vessels are
involved, manifestations include gangrene, digital loss, renal crisis, and pulmonary arterial
hypertension. While occlusive vasculopathy is a well-recognized feature of SSc, less is known
about the occurrence and the consequences of frank vascular inflammation. Albeit rare, typical
vasculitis with inflammatory infiltrates damaging blood vessels has been reported in patients
with systemic sclerosis. The distinction between SSc vasculopathy and SSc-associated vascu‐
litis can be difficult to make based on clinical presentation alone, but knowledge of the
underlying pathogenesis and histopathology can be very helpful. In the current pathogenic
model of SSc, a vascular injury of unknown cause leads to endothelial apoptosis and initiates
the process of SSc vasculopathy. Continuous endothelial dysfunction likely contributes to
activation of adventitial fibroblasts with resultant intimal proliferation, eventual luminal
narrowing, and tissue hypoxia. Histopathology of SSc vasculopathy reflects the underlying
pathogenesis, with myofibroblast proliferation and matrix deposit in the subendothelial layer
leading to obliterative thickening of vessel walls. Inflammatory infiltrates are absent, and the
internal elastic lamina remains intact. In contrast to vasculopathy, concurrent vasculitis in SSc
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shows histopathologic evidence of inflammation, with presence of mononuclear infiltrates and
destruction of the vascular wall. However, vasculitis is known to occur even in the setting of
a disease predisposing towards vasculopathy, and histology is required to distinguish the two
pathogenic processes.
SLE is a connective tissue autoimmune disease, where vasculopathy is one of the typical
symptoms. It is reported in 10-40% of patients. It occurs more often in women (80%) than in
men and may precede the development of a full-blown SLE. The differentiation of the type of
vascular complications is very difficult, sometimes impossible, and requires an in-depth
immune, histopathologic and imaging diagnostic approaches, and extensive clinical experi‐
ence. It may play a key role in the choice of treatment strategy and prediction of the patient
prognosis. Therefore, the awareness of the etiology, pathophysiology, the clinical and histo‐
pathogical setting, and SLE associated vascular complications is of great clinical significance.
Vascular lesions in SLE are commonly known as the lupus vasculopathy; a typical lupus
vasculitis with inflammatory and vascular wall necrosis and a thrombus in the lumen of
affected artery occurs less often. SLE-associated vasculitis may present different clinical
courses. The broad spectrum of symptoms includes mild forms affecting only cutaneous
vessels, and also severe, catastrophic forms, with organ complications development, and
vasculitis within the internal organs. Lupus vasculopathy is usually seen in cutaneous vessels,
in renal glomeruli, coronary and brain vessels, the brain, lung alveoli and less often in the
gastrointestinal tract. It has to be stressed that cutaneous lupus vasculopathy in systemic lupus
erythematosus occurs most often, and is reported in 94% of patients with lupus vasculitis.
Systemic rheumatoid vasculitis is a multisystem autoimmune inflammatory condition of small
and medium-sized vessels that typically affects a subset of patients with longstanding
seropositive RA and alters the course and prognosis of the disease. Mortality rates are high,
with significant morbidity. Systemic rheumatoid vasculitis refers to patients with rheumatoid
arthritis, a chronic disease with painful inflammation of the joints, who also develop inflam‐
matory disease in small and medium-sized blood vessels. The reason why systemic rheuma‐
toid vasculitis develops in some RA patients and not others is not clear. Genetic factors may
be involved. Viral infections and drug reactions have been suggested as causes of systemic
rheumatoid vasculitis. The blood vessels most often involved are arteries that bring blood to
the skin, nerves, and internal organs. Veins can also be involved. When systemic rheumatoid
vasculitis involves the small arteries and veins that nourish the skin of the fingertips and skin
around the nails, small pits in the fingertips or small sores causing pain and redness around
the nails can occur. Involvement of somewhat larger arteries and veins of the skin can cause a
painful red rash that often involves the legs. If the skin is very inflamed, ulcers can occur and
infection becomes a complicating risk. Systemic rheumatoid vasculitis that injures the nerves
can cause loss of sensation, numbness and tingling, or potentially weakness or loss of function
of the hands and/or feet. The rare systemic rheumatoid vasculitis of larger arteries can cause
complete absence of blood flow to tissue sites supplied by the affected vessel (termed occlusion,
resulting in infarction), which can cause gangrene of fingers or toes, stomach pain, cough, chest
pain, heart attack, and/or a stroke if the brain is involved. This form of systemic rheumatoid
vasculitis can also be accompanied by general symptoms such as fever, loss of appetite, weight
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loss, and loss of energy. Higher titers of rheumatoid factors, antibodies to cyclic citrullinated
peptides (anti CCP), and circulating immune complexes with lower C4 levels are detected in
the sera of patients with RA and vasculitis, compared with patients with RA only. Deposition
of rheumatoid factor-containing immune complexes likely contributes to vessel inflammation
and damage through binding to cell surface Fc receptors, activation of the complement cascade,
and release of proinflammatory cytokines.
2. Systemic sclerosis (SSc)
2.1. SSc vasculopathy
SSc is a connective tissue disease characterized by fibrosis and vasculopathy involving
multiple organ systems. Classification into diffuse or limited cutaneous forms depends on the
extent of skin thickening, with the former affecting areas proximal to the elbows or knees, and
the latter limited to the face and distal extremities [1]. Systemic sclerosis (scleroderma) has two
very different subsets: limited scleroderma and diffuse scleroderma. These can be identified
by differences in clinical findings and by the temporal relationship to vasospasm. Limited
scleroderma is so named because skin involvement is limited to the hands and face. Limited
SSc is characterized by calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclero‐
dactyly, and telangiectasia (CREST syndrome). The most common cause of death in limited
scleroderma is pulmonary hypertension or pulmonary fibrosis. Because Raynaud’s phenom‐
enon is a near universal prodrome, there are long-standing suggestions that the initial event
in limited SSc may affect the vasculature [2]. Even in localized SSc, which has fewer systemic
features, Raynaud’s progresses to peripheral ischemia with digital ulceration and loss of
fingers [3]. Although the vasospasm associated with Raynaud’s phenomenon may be prodro‐
mal, it is not itself a sufficient cause of the disease because symptoms of vasospasm can precede
diagnosis of limited SSc by many years, and the incidence of SSc in the population of people
with Raynaud’s phenomenon is very low [4]. Diffuse SSc appears with a much wider extent
of skin involvement. Patients with diffuse SSc are prone to kidney crisis and pulmonary
fibrosis. These patients develop Raynaud’s phenomenon within 1 year of onset of symptoms
but they tend to not have it as a prodrome. Both limited and diffuse SSc patients have ischemic
changes in their digits (80%–95% have Raynaud’s phenomenon), some with ulcers, gangrene,
and loss of fingers [3]. Many clinical complications of SSc are due to dysfunction of vascular
beds throughout the body. Involvement of the microvasculature leads to cutaneous and
mucosal telangiectasias, digital ulcers, and tissue ischemia. If medium-sized blood vessels are
involved, manifestations include gangrene, digital loss, renal crisis, and pulmonary arterial
hypertension [5]. While occlusive vasculopathy is a well-recognized feature of SSc, less is
known about the occurrence and the consequences of frank vascular inflammation. The
distinction between SSc vasculopathy and vasculitis can be difficult to make based on clinical
presentation alone, but knowledge of the underlying pathogenesis and histopathology can be
very helpful. In the current pathogenic model of SSc, a vascular injury of unknown cause leads
to endothelial apoptosis and initiates the process of SSc vasculopathy. Autoantibodies,
reperfusion injury, infection, and defects in vascular repair have all been implicated as possible
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triggers [6]. Increased levels of endothelial cells in the circulation have been cited as evidence
that the intactness of the vascular lining is jeopardized [6, 7]. Subsequent endothelial dysfunc‐
tion results in the imbalance of vasoactive factors: decreased levels of vasodilators such as
endothelial nitric oxide synthase and prostacyclin syntheses, as well as increased levels of the
vasoconstrictor endothelin-1 and vascular endothelial growth factor [8, 9]. Continuous
endothelial dysfunction likely contributes to activation of adventitial fibroblasts with resultant
intimal proliferation, eventual luminal narrowing, and tissue hypoxia [7, 10]. Intimal hyper‐
plasia, or more correctly the formation of a neointima, is a common response to arterial injury,
and it is a characteristic feature of the arteries in SSc. The best evidence for intimal hyperplasia
in SSc is found in a remarkable autopsy series reported by D’Angelo et al. [11] that is sum‐
marized in Table 1.
System Pathology
Pulmonary interstitial fibrosis and arterial thickening
fibrotic pleuritis
Coronary myocardial fibrosis
arteriolar concentric intimal thickening
pericarditis fibrous and adhesive
Gastrointestinal esophageal atrophy and fibrosis
lesions of reflux
small intestine atrophy and fibrosis
large intestine atrophy and fibrosis




Arterioles noninflammatory intimal proliferation in
two or more organ systems
inflammatory polyarteritis
Table 1. Summary of vascular pathology findings in SSc
Characteristic vascular changes in scleroderma also occur at the capillary level. The change
most studied in the clinical literature is at the level of the nail beds. Changes in the nailfold
capillaries are one of the first signs in SSc [12]. Because these changes have only been described
by nail bed microscopy, little is known about the mechanism of this change. However, the
morphology seen in the scleroderma nail beds closely resembles changes seen when vascular
endothelial growth factor (VEGF) is overexpressed locally [13], and nailfold changes appear
to be associated with very high levels of circulating VEGF [14]. These abnormalities have led
to speculation that endothelial death is a primary and ongoing process in SSc. Although there
is evidence from in vitro studies that SSc serum may contain antiangiogenic or other agents
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that are toxic to endothelium, apoptotic change or even increased endothelial turnover has not
been demonstrated in vivo [15, 16]. Endothelin-1 (ET-1) is a prototypical endothelial cell-
derived product, and endothelial damage leads to increased production of ET-1. Since ET-1 is
a vasoconstrictive agent, loss of normal vessel compliance and vasorelaxation may be induced
by increased levels of ET-1. In addition, ET-1 promotes fibroblast synthesis of collagen [17].
ET-1 upregulates expression of adhesion molecules, which promote the homing of pathogenic
leukocytes to the skin. Further, ET-1 can also induce myofibroblast differentiation in fibroblasts
[18]. ET-1 can induce connective tissue growth factor (CTGF), and may mediate the induction
of collagen synthesis by activation of CTGF [19]. Circulating ET-1 levels have been observed
in patients with diffuse SSc with widespread fibrosis and those with limited SSc and hyper‐
tensive disease [20], suggesting that soluble ET-1 levels may be a marker of fibrosis and
vascular damage. Thus, ET is suggested to significantly contribute to fibrogenesis, linking
between vasculopathy, and fibrosis, and the blockade of ET signalling may lead to the
reduction of fibrosis. In vitro, SSc fibroblasts synthesized increased amounts of ET-1, and
further, bosentan reduced the contractile ability of the SSc fibroblasts [18]. Therefore, a blocking
ET-1 might be expected as a benefit in reducing pulmonary fibrosis. Recently, bosentan is
demonstrated to reduce the number of newly formation of digital ulcers associated with SSc
[21]. Additionally, bosentan may reduce the sclerosis of the skin in a pilot study [22].
Nitric  oxide  (NO)  is  a  strong  vasodilator  and  inhibits  the  biochemical  effect  of  ET-1.
However, ET-1 induces inducible NO syntheses (iNOS) expression in endothelial cells [23],
and iNOS expression is detected in the endothelial cells in the lesion skin of SSc [24]. So
far,  several  reports  have  shown  impaired  NO  production  in  SSc  [24,  25],  which  may
contribute to the vascular pathogenesis of the arteriolar intimal proliferation in SSc. Thus,
an imbalance  between vasoconstriction and vasodilatation can lead to  ischemia-reperfu‐
sion  injury,  endothelial  damage  and  subsequent  increased  collagen  gene  expression  via
hypoxia. Hypoxia induces ECM proteins in cultured fibroblasts, and vascular endothelial
growth  factor  (VEGF)  overexpression  may  be  caused  in  response  to  chronic  hypoxia
condition [26].
Histopathology of SSc vasculopathy reflects the underlying pathogenesis, with myofibro‐
blast  proliferation  and  matrix  deposit  in  the  subendothelial  layer  leading  to  obliterate
thickening  of  vessel  walls.  Inflammatory  infiltrates  are  absent,  and  the  internal  elastic
lamina remains intact [27].
In contrast to vasculopathy, concurrent vasculitis in SSc shows histopathologic evidence of
inflammation, with presence of mononuclear infiltrates and destruction of the vascular wall.
Notably, both vasculopathic and vasculitic changes were seen in five of nine (55%) digital
amputation specimens from SSc patients, emphasizing that small vessel vasculitis and
stenosing vasculopathy may coexist[27]. Further support has come from autopsy studies of
SSc patients, where 24% of 58 cases showed noninflammatory intimal proliferation in two or
more organs, but 9% had features of inflammatory polyarteritis [11]. Thus, vasculitis is known
to occur even in the setting of a disease predisposing towards vasculopathy, and histology is
required to distinguish the two pathogenic processes.
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2.2. Large-vessel vasculitis associated with SSc
Giant cell arteritis is a common vasculitis of the elderly involving large- and medium-sized
arteries, typically the temporal, ophthalmic, vertebral, and axillary arteries as well as the aorta.
The American College of Rheumatology (ACR) criteria include at least three of the following:
(1) onset at age 50, (2) new headache, (3) claudication of the jaw or tongue, (4) temporal artery
tenderness to palpation or decreased pulsation, (5) ESR 50 mm/h, and (6) temporal artery
biopsy showing vasculitis with mononuclear inflammatory infiltrate or granulomatous
inflammation with presence of giant cells [28]. While giant cell arteritis is relatively common
among the vasculitides, it has only been reported in three cases of concurrent SSc, all of which
were women in their sixth decade with limited skin involvement [29-31].
Takayasu arteritis is a relatively rare large vessel vasculitis (incidence 0.4–2/million/year)
affecting mostly young women of Asian origin although the incidence among the middleaged
with atherosclerosis has been rising [32, 33]. The aorta and its main branches are typically
involved. ACR diagnostic criteria include at least three of the following: (1) onset before age
40, (2) claudication of an extremity, (3) decreased brachial artery pulse, (4) 10 mmHg in systolic
blood pressure between the arms, (5) bruit over the subclavian arteries or aorta, and (6)
stenosis/occlusion of the aorta, its major branches, or large arteries in proximal upper or lower
extremities [34]. Similar to giant cell arteritis, the histopathology in Takayasu arteritis shows
mononuclear infiltrates in the vessel wall, intimal thickening, and destruction of elastic
laminas, giant cell formation, and expansion of the adventitial layer. Elastic lamina destruction
can lead to aneurysm formation while transmural inflammation drives intimal proliferation,
adventitial scarring, and vascular lumen narrowing. Four cases of Takayasu arteritis in the
setting of SSc have been reported. As the overwhelming majority of patients with Takaysu
arteritis are female, all four of these cases were women, with ages ranging from 29 to 68 [35-38].
Three of the patients had diffuse skin involvement of SSc.
2.3. Medium- and small-vessel vasculitis associated with SSc
Polyarteritis nodosa (PAN) is a necrotizing vasculitis affecting medium-sized vessels, with a
constellation of clinical findings that reflect multiorgan involvement. It can be associated with
hepatitis B viral infection. PAN can be distinguished from the small-vessel vasculitides such
as microscopic polyangiitis by the absence of antineutrophil cytoplasmic antibodies. The ACR
diagnostic criteria for PAN include at least three of the following: (1) weight loss 4 kg, (2) livedo
reticularis, (3) testicular pain or tenderness, (4) myalgias, weakness, or leg tenderness, (5)
mono- or polyneuropathy, (6) hypertension, (7) elevated blood creatinine or urea, (8) serum
hepatitis B antigen or antibody, (9) aneurysms or occlusions of visceral arteries, or (10)
granulocytes on biopsy of small- or medium-sized arteries [39]. A recent retrospective study
of 348 patients with PAN found general symptoms in 93.1%, neurologic involvement in 79%,
and skin involvement in about 50% [40]. Five-year relapse-free survival was 59.4% for
nonhepatitis-B-associated PAN and 67% for HBV-associated PAN. Only one case of PAN has
been described in a 28-year-old woman with diffuse SSc, characterized by Raynaud’s phe‐
nomenon and skin sclerosis over the hands, arms, and chest [41].
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Primary angiitis of the central nervous system (PACNS) is a rare poorly characterized entity
affecting small- and medium-sized vessels of the central nervous system (CNS) but not organs
or vessels outside the CNS. In general, PACNS is distinguished from secondary CNS vasculitis
with the exclusion of infections, malignancy, systemic vasculitis or connective tissue disease,
or drug-induced vasculitis. Clinical presentations of PACNS include confusion, new onset
headache, seizures, stroke or cerebral hemorrhage, and myelopathy [42]. The duration from
symptom onset to diagnosis can range from 3 days to 3 years [43]. Multiple laboratory data
abnormalities can occur but none is specific for the diagnosis, with ESR described to be normal
in a number of cases. Characteristic changes on cerebral angiography include multifocal
segmental stenosis, dilatation, or occlusion of small- and medium-sized leptomeningial and
intracranial vessels as well as formation of collateral vessels. Further supportive evidence can
be obtained from leptomeningeal or parenchymal biopsies, which are specific but not sensitive
for vasculitis given the focal segmental nature of the disease; therefore, a negative biopsy does
not rule out the diagnosis. Histology can show either granulomas in small vessel walls,
lymphocytic infiltrates, or necrotizing vasculitis [43]. The rarity and heterogeneity complicate
classification, diagnosis, and management. Calabrese and Mallek have proposed the following
diagnostic criteria for PACNS: (1) recent onset of headache, confusion, or multifocal neurologic
deficits, (2) cerebral angiographic changes suggestive of vasculitis, (3) exclusion of systemic
disease or infection, and (4) leptomeningeal or parenchymal biopsy to confirm vasculitis and
to exclude infection, malignancy, and noninflammatory vascular occlusive disease [44].
However, only one case of PACNS has been described in SSc [41].
2.4. Mixed cryoglobulinemia and cryofibrinogenemiaassociated with SSc
Mixed cryoglobulinemia is the presence of polyclonal immunoglobulins that precipitate in
the  serum  with  cold  exposure,  often  secondary  to  a  connective  tissue  disease  such  as
systemic lupus erythematosus or Sjogren’s syndrome. The presence of cryoglobulins (CGs)
may be asymptomatic or may lead to manifestations of the cryoglobulinemic syndrome,
including  purpura,  arthralgia,  myalgia,  glomerulonephritis,  and  peripheral  neuropathy
[45].  The diagnosis of the latter entails a combination of clinical presentation, laboratory
testing  showing  the  presence  of  circulating  cryoglobulins,  and  histopathologic  appear‐
ance such as leukocytoclastic  vasculitis  (most  common).  Similarly,  cryofibrinogenemia is
the presence of cold-induced precipitants in the plasma but not in the serum. Connective
tissue  diseases,  malignancy,  and  infection  have  been  known  to  be  associated  with  this
condition,  which  can  be  asymptomatic  or  can  manifest  as  painful  ulcers,  purpura,  or
perniosis,  reflecting  possible  underlying  cold-induced  thromboses,  increased  blood
viscosity, or vascular reactivity. The diagnosis of clinically significant cryofibrinogenemia
requires not only circulating cryofibrinogen (CF) but also clinical features and histopatho‐
logic evidence of small-vessel thrombosis and perivascular infiltrate [46]. For both mixed
cryoglobulinemia  and  cryofibrinogenemia,  treating  the  underlying  disease  (whether
infection,  connective  tissue  disease,  or  malignancy)  can  sometimes  improve  symptoms.
Plasmapheresis  and  immunosuppression  with  glucocorticoids  and/or  cytotoxic  therapy
have also been used in severe disease although with unclear efficacy.
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Connective tissue diseases have been associated with the presence of both CG and CF, perhaps
more so than CF alone [47]. In the few studies and reports involving SSc, these cold-induced
precipitants do not appear to trigger symptoms. In one study, one out of 19 patients with both
CG and CF carried the diagnosis of SSc [47]. In another study, 10 out of 20 SSc patients had the
presence of polyclonal IgG and IgM cryoglobulins in the serum, but none exhibited clinical
signs of cryoglobulinemic syndrome [48]. In one report of long-standing SSc with the presence
of cryoglobulins (both IgG and IgM), the patient presented with paresthesias, transient
aphasia, vision changes, and delirium. Cerebral angiogram was normal, and electroencepha‐
logram revealed generalized slowing of action potentials, and computed tomography of the
extremities revealed calcinosis. While peripheral neuropathy can be a manifestation of mixed
cryoglobulinemia, central nervous system involvement would be highly unusual; therefore it,
is unclear whether the presence of cryoglobulins in this case is an incidental finding. Another
man with long-standing SSc presented with sudden onset gangrene in the fingers and toes
after cold exposure and was found to have very elevated cryofibrinogen [49].
2.5. Behcet’s disease associated with SSc
Behcet’s disease is characterized by recurrent oral aphthous ulcers and other systemic
manifestations believed to be due to systemic vasculitis, including genital aphthous ulcers,
ocular disease, skin involvement, gastrointestinal ulcers, neurologic disease, and arthritis. It
is more common along the ancient Silk Road, with 0.11% prevalence in Turkey and 2.6% per
100,000 in Southern China [50]. Diagnosis is made based on clinical features including presence
of recurrent oral aphthae plus two of the following without other systemic disease: (1) recurrent
genital aphthae, (2) eye lesions including uveitis or retinal vasculitis, (3) skin lesions including
erythema nodosum, pseudovasculitis, papulopustular lesions, or acneiform nodules, or (4)
positive pathergy test [51]. Treatment for mucocutaneous and joint disease includes colchicine
(mixed results), glucocorticoids, and other immunosuppressives such as azathioprine. More
serious disease with internal organ involvement has been treated with cyclophosphamide and
high-dose steroids. Overviewing the literature, only two cases of Behcet’s disease with
concurrent SSc have been reported [52, 53].
2.6. Relapsing polychondritis associated with SSc
Relapsing polychondritis (RPC) is an inflammatory disease of unknown etiology involving
cartilagenous tissues in multiple organs, typically the ears, nose, eyes, respiratory tract, and
joints. Vascular and neurologic complications have also been reported. Association with
systemic vasculitis, connective tissue disease, or myelodysplastic syndrome occurs in up to
one-third of the cases. The original diagnostic criteria by McAdam required three of six clinical
manifestations: (1) bilateral auricular chondritis, (2) nonerosive seronegative polyarthritis, (3)
nasal chondritis, (4) respiratory tract chondritis, (5) ocular inflammation, or (6) cochlear
and/or vestibular dysfunction [54]. The criteria were later modified to include the presence of
three or more of the above, one clinical manifestation with corroborating histology, or
chondritis at more than two sites responsive to steroids or diamino-diphenyl sulfone [55]. Only
one case of RPC has been reported in association with SSc [56]
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2.7. ANCA-associated vasculitis (AAV) in SSc patients
The spectrum of necrotizing small-vessel vasculitis known as ANCA-associated vasculitis
(AAV) includes Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), and Churg-
Strauss syndrome (CSS). While formally classified as small-vessel vasculitis, AAV can involve
medium-sized vessels. Cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCAs)
directed against proteinase 3 (PR3) are more commonly found in WGs whereas perinuclear
ANCAs (p-ANCA) targeting myeloperoxidase (MPO) are more frequently seen in MPA and
CSS. Variable organ involvement makes diagnosis a challenge, with alveolar hemorrhage and
crescentic glomerulonephritis frequently occurring in WG and MPA, while polyneuropathy
can be seen in ANCA-associated CSS [57]. Disease stage can range from localized without end-
organ damage to severe generalized with organ failure. Of all the small vessel vasculitides,
AAV is the most frequently reported in association with SSc, raising the question whether an
overlap syndrome exists that combines features from both diseases. A study by Rho et al. found
31 reports containing 63 cases of AAV in SSc up to 1994 [58].
While lumen-occlusive vasculopathy is a prominent feature of SSc, frank vasculitis may also
occur. Coexistent SSc and vasculitis have been reported for vessels of all sizes, either before or
after SSc diagnosis, and in either SSc subtype (limited or diffuse).
3. Systemic lupus erythematosus (SLE)
3.1. Vascular involvement in SLE
SLE is a connective tissue autoimmune disease, where vasculopathy is one of the most typical
symptoms [59]. Vascular involvement is frequent in SLE patients and represents the most
frequent cause of death in established disease. In this context, vasculopathy can be directly
aetiologically implicated in the pathogenesis of the disease, presenting as an acute/subacute
manifestation of lupus (e.g., antiphospholipid syndrome (APS), lupus vasculitis). Besides overt
vessel obstruction, vascular disease in lupus, especially when affecting medium- and small-
sized vessels, may contain both vasculopathic and vasculitic pathophysiologic parameters.
Livedoid vasculopathy, a condition which can be observed in patients with systemic lupus
erythematosus/antiphospholipid syndrome or specific forms of systemic vasculitis (mainly
polyarteritis nodosa and cryoglobulinemia), is associated with chronic ulcerations of the lower
extremities and characterized by uneven perfusion [60]. The pathogenesis of livedoid vascul‐
opathy has not been fully elucidated, or rather, cannot be solely attributed to a particular
mechanism, as both hypercoagulable states, as well as autoimmune diseases, appear to
associate with and contribute to its development [61].
The typical histological findings show dermal blood vessel occlusion [62]. The histopatho‐
logical findings of intravascular fibrin, segmental hyalinization, and endothelial prolifera‐
tion  clearly  support  the  thrombotic  parameter  of  its  pathogenesis  [63].  The  presence  of
immunoreactants in the vessel wall and circulating immune complexes (such as rheuma‐
toid factor)  are  in  favor  of  its  immunological  component;  the  absence however  of  fibri‐
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noid  necrosis  and  inflammatory  infiltration  of  the  vessel  wall  differentiates  livedoid
vasculopathy from true vasculitides.
It is reported in 10–40% of patients. It occurs more often in women (80%) than in men and may
precede the development of a full-blown SLE [64]. Vascular lesions in SLE are commonly
known as the lupus vasculopathy; a typical lupus vasculitis with inflammatory and vascular
wall necrosis and a thrombus in the lumen of affected artery occurs less often [65-67]. However,
the rate of thrombotic events is higher in patients with disease of recent onset, when compared
to patients with other autoimmune diseases and remains so throughout the course of the
disease [68]; in the LUMINA study, which included multiethnic SLE patients of recent
diagnosis, age, damage accrual at enrolment, and antiphospholipid antibodies, as well as the
use of higher dosages of glucocorticoids were associated with a shorter time interval to
thrombotic events [69]. Appel et al. [66] provided an SLE vasculopathy classification including:
non complicated vascular deposits of immune complexes, noninflammatory necrotic vascul‐
opathy, thrombotic microangiopathy and true lupus vasculitis. Of all lupus vasculitis, cases
more than 60% is leucocytoclastic inflammation, 30% is vasculitis with cryoglobulinemia, and
systemic vasculitis resembling polyarteritis nodosa constitutes about 6% of SLE vasculitides
patients [66, 70-72]. Other clinical syndromes of vasculopathy in patients from the discussed
group include thrombocytopenia with thrombotic purpura, venous thrombosis, antiphospho‐
lipid syndrome and urticaria vasculitis, reported in 5% of SLE patients [66]. The SLE associated
vasculitis may present different clinical courses. The broad spectrum of symptoms includes
mild forms affecting only cutaneous vessels, and also severe, catastrophic forms, with organ
complications development, and vasculitis within the internal organs [73, 74]. Lupus vasculitis
is usually seen in cutaneous vessels, in renal glomeruli, coronary and brain vessels, the brain,
lung alveoli and less often in the gastrointestinal tract [59]. It has to be stressed that cutaneous
lupus vasculopathy in SLE occurs most often, and is reported in 94% of patients with lupus
vasculitis [75, 76]. Mild forms are characterized by purpura, urticaria lesions or bullous lesions
of extremities, and livedo reticularis on the trunk.
It has been demonstrated that internal organ vessels are affected in 18% of SLE vasculitis
patients. Renal vasculitis takes the shape of focal segmental glomerulitis with development of
fibrinoid necrosis [59]. Lung vasculitis takes the form of necrotic alveolar capillaritis predis‐
posing to pulmonary hemorrhage [59]. Brain vasculitis occurs only in about 10% of SLE
patients, and associated clinical symptoms are very variable; from a mild cognitive dysfunction
to severe psychosis and convulsions, local ischemia and strokes [59, 77]. The peripheral
nervous system may also be affected by lupus vasculopathy leading to multifocal inflamma‐
tory mononeuropathies [59]. Mesothelium vasculitis may also occur and lead to gastrointes‐
tinal hemorrhage or perforation [59]
3.2. Antiphospholipid syndrome
The clinical APS, an autoimmune syndrome usually developing in the context of SLE, is a
condition defined as a predisposition for arterial and/or venous thromboses and/or recurrent
miscarriages or other obstetric emergencies (e.g., premature birth, preeclampsia) in association
with hematologic abnormalities and specific antibodies targeted against phospholipid-
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binding plasma proteins [78]. It has been suggested that endothelial damage of whatever origin
exposes endothelial cell phospholipids, which enables the adhesion of antibodies directed
against phospholipids (aPL) [75]. The pathogenetic action mechanisms of aPL antibodies are
variable. When binding with membrane phospholipids aPL antibodies may inhibit reactions
catalyzed by them in the coagulation cascade, for example through inhibition of C and S protein
activation [79]. These antibodies may also activate endothelial cells thrombin formation [79].
The binding of aPL antibodies with platelet membrane phospholipids binding protein
predisposes to platelet activation and adhesion, with consequent thrombus formation. These
antibodies probably also participate in the complement system activation [79]. As a result, the
aPL antibodies demonstrate proadhesive, proinflammatory and prothrombotic effects on
endothelial cells [79].Thrombosis within the context of APS may occur even in histologically
normal vessels. However, in the majority of aPL-positive patients, seropositivity per se does
not suffice for the development of clinical events. Thrombotic events seem to occur more
readily in SLE patients with coexistent atherosclerosis [80]. Recently, the presence of micro‐
angiopathy, defined as capillary microhemorhages, and diagnosed with the aid of capillaro‐
scopy, has been proposed as an augmentary screening tool for aPL-seropositive patients who
are prone to develop clinical thrombotic manifestations [81].
3.3. Lupus vasculitis
Distinction of inflammatory lupus vasculitis from APS, which may present with similar clinical
manifestations, is of major significance in terms of clinical management. Inflammatory
vascular disease is triggered by the in situ formation, or the deposition, of immune complexes
within the vessel wall.
Vasculitis may manifest in as high as 56% of SLE patients throughout their life, in contrast to
antiphospholipid syndrome which has a prevalence of 15%. Patients with vasculitis are mainly
male and tend to be of younger age [82]. Antibodies against endothelial cells have been
identified as a major endothelial cell cytotoxic effector and have been implicated in the
pathogenesis of several connective tissue diseases, predominantly vasculitides [83]. More than
80% of systemic lupus erythematosus patients are positive for antiendothelial cell antibodies
(AECAs) [84]. Other forms of SLE-related vasculitis include drug-induced vasculitis [85] and
infection-induced vasculitis [86] either through direct compromise of the vascular wall by
pathogens, or through antigen-induced autoimmune and inflammatory processes. Some
drugs may play a role in the induction of inflammatory vascular lesions in SLE. The drug
molecule may act as a hapten, which as a result of autoantigen binding alters the antigen
properties. Several SLE inducing drugs are listed below: penicillins, allopurinol, thiazides,
pyrazolones, retinoids, streptokinase, cytokines, monoclonal antibodies, chinolons, hydan‐
toin, carbamazepine and other anticonvulsants [59, 87]. Vasculitis may be a result of direct
attack of microorganisms on the blood vessel wall or may be caused by infected thrombotic
mass [74]. Hepatitis C virus may take part in vasculitis development, with the cryoglobulin
presence [88]]. There is an unexplained relationship between blood cryoglobulins and hepatitis
C [74]. The following mechanisms leading to viral and bacterial vasculitis in SLE have been
suggested: [1] the viruses directly attack the vascular wall inducing an inflammatory process,
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[2] some of them, as cytomegalovirus, may permeate and activate endothelial cells leading to
vasculitis and [3] bacterial Staphylococcus antigens, as for example neutral phosphatase, may
bind with basement membranes and adhere specifically to IgG, which in turn induces an
immune response and an inflammatory process.
4. Rheumatoid arthritis (RA)
RA is a chronic inflammatory systemic disorder which primarily involves the joint synovial
membrane. The purpose of this chapter section is to describe the occurrence and pathophysi‐
ology of vasculitis and vasculopathy in RA.
4.1. Rheumatoid vasculitis
Rheumatoid vasculitis typically affects small and medium-size blood vessels. It is associated
with high rates of premature mortality with up to 40% of patients dying by 5 years as well as
significant morbidity due to both organ damage from vasculitis and consequences of the
treatment [89, 90]. Diagnostic criteria for systemic rheumatoid vasculitis were proposed in 1984
by Scott et al. [91], although the classification of RA-associated vasculitis remains poorly
codified. It shares many characteristics with a classic polyarteritis nodosa and may affect
peripheral nerves, causing mononeuritis multiplex, skin, gastrointestinal tract, and other
organs, but it is not usually associated with the development of microaneurysms [92]. High
levels of circulating immune complexes have been observed in patients with rheumatoid
vasculitis [93], and in particular high serum levels of rheumatoid factor are often detected at
the time of onset of vasculitis [94]. Deposition of immune complexes most likely contributes
to small vessel inflammation and organ damage. Anti CCP levels also tend to be higher in
patients with RA who have systemic vasculitis than in those who do not. Rheumatoid vasculitis
has been reported in a substantial number of patients with RA [95]. It is more common in men
and patients with longstanding disease [91]. The annual incidence of rheumatoid vasculitis in
men to be 15.8 per million and in women, 9.4 per million [95]. Nevertheless, the 30-year
incidence of vasculitis in patients with RA was estimated to be 3.6% [96].
Predictors of vasculitis in RA patients include clinical and generic factors (Table 2) [97-103].
Smoking, which is also a risk factor for development of RA in the general population [104], is
associated with an increased risk of vasculitis among patients with RA [99, 100]. Rheumatoid
nodules early during the disease predict the occurrence of systemic rheumatoid vasculitis [97,
98]. However, genetic predisposition toward developed RA, as HLA-DRB1-shared epitope
genotypes is strongly associated with extraarticular disease manifestations such as rheumatoid
vasculitis [101, 102]. In particular, double dose of RA-associated HLADRB1*04 alleles is
associated with an increased risk of vasculitis [105]. Rheumatoid vasculitis is associated with
an increased mortality as compared with that in patients with RA in general [89]. In particular,
a poor survival has been observed after diagnosis of vasculitis-related neuropathy [106]. In
such patients, a low serum level of complement factor C4 is a negative prognostic marker [90].
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The increased mortality may be due to a high risk of cardiovascular comorbidity [107, 108] and
severe infections [109].
Marker Pathophysiological explanation
Rheumatoid nodules sign of microvascular extraarticular inflammation
Smoking vascular damage, immunomodulation
HLA-DRB1*04/04 double gene dose selection and activation of T cells
HLA-C*3 allele activation of cytotoxic CD28null T cells
KIR2DS2 allele activation of cytotoxic CD28null T cells
KIR, killer immunoglobulin-like receptors
Table 2. Predictors for vasculitis in RA patients
According to the data from the literature very little is known of what events trigger the
development of vasculits in RA patients at a particular time point. This probably includes a
number of different infectious agents and other immune exposures. For example, rare cases
of rheumatoid vasculitis following influenza vaccination have been described [110].
4.2. Clinical manifestations of rheumatoid vasculits
Rheumatoid vasculitis often affects more than single organ. Patients may develop nailfold
infarcts and leg ulcers. These patients may go on to have more widespread vascular disease
but usually do not [111]. Cutaneous manifestations of rheumatoid vasculitis may present as
digital digital infarcts, livedo, palpable purpura, bulla, ulcerations, painful nodules, or
gangrene. Histologically, rheumatoid vasculitis involves blood vessels of the small arteries,
and all layers of the vessel wall are infiltrated by neutrophils, lymphocytes, and plasma cells.
Cutaneous manifestation of rheumatoid vasculitis is classified into three grades: severe,
moderate, and mild. The severe type presents with digital gangrene, nail fold infarcts, large
cutaneous ulcers; the moderate type presents with palpable purpura; and the mild type
presents with nailfold telangiectasias with thromboses, minute digital ulcerations, petechiae,
and livedo reticularis. Minor bleeding from the nail folds, finger pulp, and the edge of the nails
results from digital infarcts (isolated nailfold vasculitis) [112]. RA patients who develop leg
ulcers and digital ulcers should be more closely monitored, especially patients who have high
titers of rheumatoid factor, positive anti CCPs, cryoglobulins, and low complements, as more
ominous manifestations of RA are more likely to occur in these patients [113]. The diagnosis
of leg ulcers in patients with RA is often associated with trivial trauma. There is often an
underlying vasculitis, which promotes the lesion.
Systemic vasculitis in RA usually occurs in patients who have longstanding disease, generally
of more than 10-year duration. Even so, it may occur at any time during the disease course,
and, irrespective of when it occurs, it is associated with a poor prognosis. From a clinical
standpoint, patients have more severe RA with destructive joint disease and other features of
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extraarticular disease [98]. Patients with Felty’s syndrome are particularly prone to develop
rheumatoid vasculitis. The appearance of rheumatoid vasculitis may be associated with a rise
in acute-phase markers, including the sedimentation rate and C-reactive protein, together with
longstanding thrombocytosis and anemia of chronic disease [98]. RA-associated vasculitis may
involve any blood vessel bed in the body, including cerebral, mesenteric, and coronary arteries
[114]. More severe features of rheumatoid vasculitis are frank infarctions of the digits and
mononeuritis multiplex [113, 115]. Unfortunately, patients with systemic rheumatoid vascu‐
litis may develop mononeuritis multiplex [116]. Mononeuritis in RA often begins with
numbness and then progresses to tingling and muscle weakness. Initially, the mononeuritis is
asymmetric but may become symmetrical. Other early manifestations of rheumatoid vasculitis
include pericarditis and scleritis. Rheumatoid vasculitis is also strongly associated with the
presence of rheumatoid nodules, and most RA patients with vasculitis have nodulosis [98].
Rheumatoid vasculitis may also affect the coronary arteries. In the kidney, renal artery
involvement, as occurs in polyarteritis nodosa with vasculitis, may cause renal failure,
although the disorder should be distinct from polyarteritis nodosa [117, 118].
Rheumatoid vasculitis is an unusual complication of RA, which has profound impact on
disease severity and life expectancy of patients who develop this extraarticular disease
manifestation.
4.3. Angiogenesis in RA
RA is the rheumatic disease in which the role of angiogenesis has been studied most exten‐
sively; it is characterized by excessive angiogenesis [119]. Proangiogenic mediators associated
with RA include the following: growth factors such as VEGF; cytokines such as TNF-α (which
has many effects in addition to angiogenesis); chemokines such as IL-8; and other mediators,
including ET-1. VEGF, an endothelial selective mitogen that is secreted predominantly by
macrophages, is an important cytokine in both angiogenesis and vasculogenesis [120]. In RA,
VEGF expression is induced by hypoxia. Hypoxic environment of the inflamed RA joint
activates the VEGF gene via binding of hypoxia inducible factor. This in turn augments IL-1
or transforming growth factor (TGF)-β induced synovial fibroblast VEGF [121], which
contributes significantly to angiogenesis in the synovium and progression of RA. Evidence of
the importance of TNF-α as a proangiogenic mediator in RA is illustrated by the effect of giving
anti-TNF-a to patients with RA. Administration of anti-TNF-α drugs to patients with RA leads
to vascular deactivation, including decreased angiogenesis and endothelial cell markers [122].
Chemokines are also very important in angiogenesis in RA. Recent studies have shown that
the chemokine IL-8/CXC chemokine ligand (CXCL)8 plays a role in the pathogenesis of RA
synovitis. This molecule is angiogenic and appears to be responsible for much of the macro‐
phage-derived angiogenic activity seen in RA [123]. In addition to its well recognized effects
as a potent endogenous vasoconstrictor and smooth muscle mitogen, ET-1 also appears to have
proangiogenic effects in some rheumatic diseases. In patients with RA, levels of ET-1 in
synovial fluid, serum and plasma are elevated in comparison with those in normal individuals
[124-127]. Although this clearly does not demonstrate a causal role for ET-1 in the pathophysi‐
ology of RA, it may suggest some degree of involvement.
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4.4. Vasculopathy in RA
Atherogenesis  is  a  precocious  feature  in  RA,  as  extraarticular  manifestation  of  the  syn‐
drome, and might be defined as rheumatoid vasculopathy. RA has been associated with
precocious and accelerated atherosclerosis [128-134] and with increased CV morbidity and
mortality  [135].  Notably,  atherosclerosis  has  been  proposed  as  extraarticular  manifesta‐
tion  of  the  disease  [130].  Several  disease-related  mechanisms  may  be  involved  in  the
development  of  premature  vascular  damage  in  RA,  including  increased  synthesis  of
proinflammatory mediators (such as cytokines, chemokines, adhesion molecules), autoanti‐
bodies  against  endothelial  cell  components,  perturbations  in  T-cell  subsets,  genetic
polymorphisms, hyperhomocysteinemia, oxidative stress, and abnormal vascular repair, as
well as iatrogenic factors [136, 137]. Hyperhomocysteinemia, which is a common finding
in patients with RA, is a further contributor to the impaired endothelial function, potenti‐
ates  the  oxidation  of  lipoproteins,  and  has  prothrombotic  effects  [138].  Inflammation
severity was found to be associated with functional and structural arterial wall changes in
patients  with  recent  RA  onset,  and  early  control  of  inflammation  is  associated  with
improved arterial function that may reduce atherosclerosis progression [139].
5. Conclusion
Vascular damage in humans develops on various grounds. It may be inflammatory or
noninflammatory. The damages may be induced by environmental factors (toxic agents,
medications, microorganisms), through cancer as a paraneoplastic syndrome, or may be
directly associated with an active immune process. Distinguishing between noninflammatory
vasculopathy and vasculitis can pose a significant diagnostic challenge in the absence of
histological examination. Vasculitis should not be confused with vasculopathy, which simply
means something is wrong with the blood vessels, although it's usually not vasculitis. When
a blood vessel becomes inflamed and narrowed, blood supply to that area can become partially
or completely blocked. Complete blockage is called occlusion; it causes the vessel wall to swell
and makes things stick to the wall -- so a clot forms. When vasculitis interferes with circulation
in any part of the body, it causes local tenderness and pain. If the blood vessels are close to the
skin, characteristic rashes occur. Depending on where the blockage occurs, almost any organ
in the body can be affected. However, vasculopathy can also block blood vessels, but it does
not cause the fever, pain, and local tenderness associated with vasculitis.
As this chapter illustrates, vascular involvement is an important part in the RA, SLE and SSc
pathogenesis. Vasculitis in RA is generally associated with longstanding disease, has an
important impact on s patient’s well being and markedly influences patient life expectancy.
Predictors of vasculitis in RA patients include clinical and genetic factors. Vaculitis in RA
generally affects small and medium-seized vessels. It shares many characteristics with a classic
polyarteritis nodosa and may affect peripheral nerves, causing mononeuritis multiplex, skin,
gastrointestinal tract and other organs. It is not usually associated with the development of
microaneurysms. Atherogenesis is a precocious feature in RA, as extraarticular manifestation
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of the syndrome, and might be defined as rheumatoid vasculopathy. Several disease-related
mechanisms may be involved in the development of premature vascular damage in RA.
Increased synthesis of proinflammatory mediators, autoantibodies against endothelial cell
components, perturbations in T-cell subsets, genetic polymorphisms, hyperhomocysteinemia,
oxidative stress and abnormal vascular repair are associated with atherosclerosis in RA.
Vascular involvement in SLE may be of inflammatory or thrombotic origin. Both mechanisms
involve the immune system. The activation and consequent endothelial lesions play a very
important role in the disease pathogenesis. The common hypothesis for vasculopathy in SLE
concerns the endothelial deposition of circulating immune complexes. There are many various
autoantibodies in SLE as circulating immune complexes which directly or indirectly affect
endothelial cells, causing chronic vessel wall damage. Furthermore, vasculitis in SLE is
proatherogenic condition and is characterized by leucocytes activation and production of
cytokine and other inflammatory mediators.
Although SSc is considered a fibrosing disease, vascular involvement plays a major role in
pathogenesis and organ dysfunction. SSc vascular disease involves vasculopathy with luminal
occlusion, thrombosis and vasospasm. The vascular pathology in SSc is not necessarily an
inflammatory process and would be better be characterised as a vasculopathy in the absence
of vasculitis. In the current pathogenic model of SSc, a vascular injury of unknown cause leads
to endothelial apoptosis and initiates the process of SSc vasculopathy. Histopathology of SSc
vasculopathy reflects the underlying pathogenesis, with myofibroblast proliferation and
matrix deposit in the subendothelial layer leading to obliterative thickening of vessel walls.
Inflammatory infiltrates are absent, and the internal elastic lamina remains intact. In contrast
to vasculopathy, concurrent vasculitis in SSc shows histopathological evidence of inflamma‐
tion with presence of mononuclear infiltrates and destruction of the vascular wall.
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